FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1935607410> ?p ?o ?g. }

• W1935607410 endingPage "580" @default.
• W1935607410 startingPage "574" @default.
• W1935607410 abstract "OBJECT The optimal mean arterial pressure (MAP) for spinal cord perfusion after trauma remains unclear. Although there are published data on MAP goals after spinal cord injury (SCI), the specific blood pressure management for acute traumatic central cord syndrome (ATCCS) and the implications of these interventions have yet to be elucidated. Additionally, the complications of specific vasopressors have not been fully explored in this injury condition. METHODS The present study is a retrospective cohort analysis of 34 patients with ATCCS who received any vasopressor to maintain blood pressure above predetermined MAP goals at a single Level 1 trauma center. The collected variables were American Spinal Injury Association (ASIA) grades at admission and discharge, administered vasopressor and associated complications, other interventions and complications, and timing of surgery. The relationship between the 2 most common vasopressors-dopamine and phenylephrine-and complications within the cohort as a whole were explored, and again after stratification by age. RESULTS The mean age of the ATCCS patients was 62 years. Dopamine was the most commonly used primary vasopressor (91% of patients), followed by phenylephrine (65%). Vasopressors were administered to maintain MAP goals fora mean of 101 hours. Neurological status improved by a median of 1 ASIA grade in all patients, regardless of the choice of vasopressor. Sixty-four percent of surgical patients underwent decompression within 24 hours. There was no observed relationship between the timing of surgical intervention and the complication rate. Cardiogenic complications associated with vasopressor usage were notable in 68% of patients who received dopamine and 46% of patients who received phenylephrine. These differences were not statistically significant (OR with dopamine 2.50 [95% CI 0.82-7.78], p = 0.105). However, in the subgroup of patients > 55 years, dopamine produced statistically significant increases in the complication rates when compared with phenylephrine (83% vs 50% for dopamine and phenylephrine, respectively; OR with dopamine 5.0 [95% CI 0.99-25.34], p = 0.044). CONCLUSIONS Vasopressor usage in ATCCS patients is associated with complication rates that are similar to the reported literature for SCI. Dopamine was associated with a higher risk of complications in patients > 55 years. Given the increased incidence of ATCCS in older populations, determination of MAP goals and vasopressor administration should be carefully considered in these patients. While a randomized control trial on this topic may not be practical, a multiinstitutional prospective study for SCI that includes ATCCS patients as a subpopulation would be useful for examining MAP goals in this population." @default.
• W1935607410 created "2016-06-24" @default.
• W1935607410 creator A5002749837 @default.
• W1935607410 creator A5008043111 @default.
• W1935607410 creator A5016967222 @default.
• W1935607410 creator A5019326045 @default.
• W1935607410 creator A5024399452 @default.
• W1935607410 creator A5026867191 @default.
• W1935607410 creator A5031038037 @default.
• W1935607410 creator A5035979238 @default.
• W1935607410 creator A5043714838 @default.
• W1935607410 creator A5076261073 @default.
• W1935607410 creator A5079134143 @default.
• W1935607410 date "2015-11-01" @default.
• W1935607410 modified "2023-10-13" @default.
• W1935607410 title "Complications and outcomes of vasopressor usage in acute traumatic central cord syndrome" @default.
• W1935607410 cites W1580467581 @default.
• W1935607410 cites W1751000351 @default.
• W1935607410 cites W1753627328 @default.
• W1935607410 cites W1977677505 @default.
• W1935607410 cites W1990200376 @default.
• W1935607410 cites W1990564621 @default.
• W1935607410 cites W2001657855 @default.
• W1935607410 cites W2010811655 @default.
• W1935607410 cites W2021956285 @default.
• W1935607410 cites W2025977536 @default.
• W1935607410 cites W2028815903 @default.
• W1935607410 cites W2029411057 @default.
• W1935607410 cites W2029980842 @default.
• W1935607410 cites W2031211371 @default.
• W1935607410 cites W2034231651 @default.
• W1935607410 cites W2050080200 @default.
• W1935607410 cites W2071628059 @default.
• W1935607410 cites W2074834108 @default.
• W1935607410 cites W2093448122 @default.
• W1935607410 cites W2095944485 @default.
• W1935607410 cites W2114070167 @default.
• W1935607410 cites W2119094604 @default.
• W1935607410 cites W2141244009 @default.
• W1935607410 cites W2143053719 @default.
• W1935607410 cites W2162556070 @default.
• W1935607410 cites W4252752857 @default.
• W1935607410 doi "https://doi.org/10.3171/2015.2.spine14746" @default.
• W1935607410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26230417" @default.
• W1935607410 hasPublicationYear "2015" @default.
• W1935607410 type Work @default.
• W1935607410 sameAs 1935607410 @default.
• W1935607410 citedByCount "45" @default.
• W1935607410 countsByYear W19356074102015 @default.
• W1935607410 countsByYear W19356074102016 @default.
• W1935607410 countsByYear W19356074102017 @default.
• W1935607410 countsByYear W19356074102018 @default.
• W1935607410 countsByYear W19356074102019 @default.
• W1935607410 countsByYear W19356074102020 @default.
• W1935607410 countsByYear W19356074102021 @default.
• W1935607410 countsByYear W19356074102022 @default.
• W1935607410 countsByYear W19356074102023 @default.
• W1935607410 crossrefType "journal-article" @default.
• W1935607410 hasAuthorship W1935607410A5002749837 @default.
• W1935607410 hasAuthorship W1935607410A5008043111 @default.
• W1935607410 hasAuthorship W1935607410A5016967222 @default.
• W1935607410 hasAuthorship W1935607410A5019326045 @default.
• W1935607410 hasAuthorship W1935607410A5024399452 @default.
• W1935607410 hasAuthorship W1935607410A5026867191 @default.
• W1935607410 hasAuthorship W1935607410A5031038037 @default.
• W1935607410 hasAuthorship W1935607410A5035979238 @default.
• W1935607410 hasAuthorship W1935607410A5043714838 @default.
• W1935607410 hasAuthorship W1935607410A5076261073 @default.
• W1935607410 hasAuthorship W1935607410A5079134143 @default.
• W1935607410 hasBestOaLocation W19356074101 @default.
• W1935607410 hasConcept C118552586 @default.
• W1935607410 hasConcept C126322002 @default.
• W1935607410 hasConcept C141071460 @default.
• W1935607410 hasConcept C167135981 @default.
• W1935607410 hasConcept C2776452961 @default.
• W1935607410 hasConcept C2777952589 @default.
• W1935607410 hasConcept C2777953023 @default.
• W1935607410 hasConcept C2778334475 @default.
• W1935607410 hasConcept C2780110798 @default.
• W1935607410 hasConcept C2780775167 @default.
• W1935607410 hasConcept C42219234 @default.
• W1935607410 hasConcept C71924100 @default.
• W1935607410 hasConcept C72563966 @default.
• W1935607410 hasConcept C81182388 @default.
• W1935607410 hasConcept C84393581 @default.
• W1935607410 hasConceptScore W1935607410C118552586 @default.
• W1935607410 hasConceptScore W1935607410C126322002 @default.
• W1935607410 hasConceptScore W1935607410C141071460 @default.
• W1935607410 hasConceptScore W1935607410C167135981 @default.
• W1935607410 hasConceptScore W1935607410C2776452961 @default.
• W1935607410 hasConceptScore W1935607410C2777952589 @default.
• W1935607410 hasConceptScore W1935607410C2777953023 @default.
• W1935607410 hasConceptScore W1935607410C2778334475 @default.
• W1935607410 hasConceptScore W1935607410C2780110798 @default.
• W1935607410 hasConceptScore W1935607410C2780775167 @default.
• W1935607410 hasConceptScore W1935607410C42219234 @default.
• W1935607410 hasConceptScore W1935607410C71924100 @default.
• W1935607410 hasConceptScore W1935607410C72563966 @default.

• next